Special Issue "Advances in Acute Myeloid Leukemia"
Deadline for manuscript submissions: closed (30 November 2020).
2. University of Antwerp, Vaccine & Infectious Disease Institute, Laboratory of Experimental Hematology, Tumor Immunology Group, Antwerp, Belgium
Interests: acute myeloid leukemia; immunotherapy; dendritic cell vaccines; CAR-T cells
Interests: acute myeloid leukemia; antibody-based therapy; CD33; clinical trials; minimal residual disease
Special Issues, Collections and Topics in MDPI journals
Special Issue in Hemato: Current Topics in Acute Myeloid Leukemia
The prognosis of adult patients with acute myeloid leukemia (AML) remains poor. The 5-year overall survival rate of AML is approximately 25%, a statistic that has largely remained unchanged over the last decades. In recent years, we have witnessed the advent of several new treatments including targeted therapies, monoclonal antibodies and other immunotherapies. The rapid discovery of novel treatments along with advances in supportive care justify the expectation that the outcomes of AML patients can be finally improved in the near future.
The focus of this Special Issue is to highlight these new advances in the treatment of AML.
Dr. Sébastien Anguille
Dr. Roland B. Walter
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- acute myeloid leukemia
- targeted therapies
- monoclonal antibodies
- gene-modified T cells